Mark A Glickman sold $2,165 of TXMD
Co-Chief Executive Officer at TherapeuticsMD, Inc.. 440 shares at an average of $4.92, traded Dec 6, 2022, filed Dec 9, 2022.
Score components
- +25RoleCEO
- 0Trade size$2k at market
- +10Share of holdings soldSold 25% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001209191-22-060586, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 6, 2022 | MOption exercise Common Stock | +1,734 | $0.00 | $0 | 1,734 | Dec 9, 2022 |
| Dec 6, 2022 | SOpen-market sale Common Stock | -440 | $4.92 | $2,165 | 1,294 | Dec 9, 2022 |
| Dec 6, 2022 | MOption exercise Restricted Stock Unitsderivative | -1,734 | $0.00 | $0 | 3,466 | Dec 9, 2022 |
Related signals
Other insiders at TherapeuticsMD, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | TXMDbuy TherapeuticsMD, Inc. | Tommy G Thompson director | $14k 8,400 shares | +57% | |
| 33Weak | TherapeuticsMD, Inc. | Marlan D Walker Chief Executive Officer | $489 490 shares | +1% | |
| 23Weak | TherapeuticsMD, Inc. | Tommy G Thompson director | $326 325 shares | +2% | |
| 33Weak | TherapeuticsMD, Inc. | Marlan D Walker Chief Executive Officer | $1,994 2,303 shares | +3% | |
| 31Weak | TXMDbuy TherapeuticsMD, Inc. | Cooper C. Collins director | $7,099 4,094 shares | +9% | |
| 23Weak | TXMDbuy TherapeuticsMD, Inc. | Cooper C. Collins director | $2,039 1,200 shares | +3% | |
| 21Weak | TXMDsell TherapeuticsMD, Inc. | Marlan D Walker Chief Executive Officer | $44k 19,050 shares | -23% | |
| 30Weak | TherapeuticsMD, Inc. | Brian Bernick Co-Chief Executive Officer | $6,621 1,255 shares | -24% | |
| 27Weak | TherapeuticsMD, Inc. | Michael C Donegan Interim CFO/CAO/VP of Finance | $4,345 910 shares | -17% | |
| 50Moderate | TherapeuticsMD, Inc. | Gail K Naughton director | $21k 3,922 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.